271 related articles for article (PubMed ID: 37146911)
1. Molecular Profiling Provides Clinical Insights Into Targeted and Immunotherapies as Well as Colorectal Cancer Prognosis.
Guo L; Wang Y; Yang W; Wang C; Guo T; Yang J; Shao Z; Cai G; Cai S; Zhang L; Hu X; Xu Y
Gastroenterology; 2023 Aug; 165(2):414-428.e7. PubMed ID: 37146911
[TBL] [Abstract][Full Text] [Related]
2. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
[TBL] [Abstract][Full Text] [Related]
3. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
4. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
Picard E; Verschoor CP; Ma GW; Pawelec G
Front Immunol; 2020; 11():369. PubMed ID: 32210966
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.
Rosenbaum MW; Bledsoe JR; Morales-Oyarvide V; Huynh TG; Mino-Kenudson M
Mod Pathol; 2016 Sep; 29(9):1104-12. PubMed ID: 27198569
[TBL] [Abstract][Full Text] [Related]
6. Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer - possible implications for immunotherapy.
Edin S; Gylling B; Li X; Stenberg Å; Löfgren-Burström A; Zingmark C; van Guelpen B; Ljuslinder I; Ling A; Palmqvist R
Br J Cancer; 2024 Jan; 130(1):143-150. PubMed ID: 38040818
[TBL] [Abstract][Full Text] [Related]
7. Genomic and prognostic heterogeneity among RAS/BRAF
Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
[TBL] [Abstract][Full Text] [Related]
8. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
[TBL] [Abstract][Full Text] [Related]
9. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
[TBL] [Abstract][Full Text] [Related]
10. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
[TBL] [Abstract][Full Text] [Related]
12. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
13. Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy.
Hua H; He W; Chen N; He Y; Wu G; Ye F; Zhou X; Li Y; Ding Y; Zhong W; Teng L; Jiang W; Sheng Q
Front Immunol; 2022; 13():974793. PubMed ID: 36700211
[TBL] [Abstract][Full Text] [Related]
14. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women.
Samadder NJ; Vierkant RA; Tillmans LS; Wang AH; Weisenberger DJ; Laird PW; Lynch CF; Anderson KE; French AJ; Haile RW; Potter JD; Slager SL; Smyrk TC; Thibodeau SN; Cerhan JR; Limburg PJ
Gastroenterology; 2013 Aug; 145(2):348-56.e1-2. PubMed ID: 23665275
[TBL] [Abstract][Full Text] [Related]
15. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.
Élez E; Mulet-Margalef N; Sanso M; Ruiz-Pace F; Mancuso FM; Comas R; Ros J; Argilés G; Martini G; Sanz-Garcia E; Baraibar I; Salvà F; Noguerido A; Cuadra-Urteaga JL; Fasani R; Garcia A; Jimenez J; Aguilar S; Landolfi S; Hernández-Losa J; Braña I; Nuciforo P; Dienstmann R; Tabernero J; Salazar R; Vivancos A
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613564
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
Cushman-Vokoun AM; Stover DG; Zhao Z; Koehler EA; Berlin JD; Vnencak-Jones CL
Clin Colorectal Cancer; 2013 Sep; 12(3):168-78. PubMed ID: 23773459
[TBL] [Abstract][Full Text] [Related]
17. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers.
Kim JH; Seo MK; Lee JA; Yoo SY; Oh HJ; Kang H; Cho NY; Bae JM; Kang GH; Kim S
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903553
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features.
Nazemalhosseini-Mojarad E; Mohammadpour S; Torshizi Esafahani A; Gharib E; Larki P; Moradi A; Amin Porhoseingholi M; Asadzade Aghdaei H; Kuppen PJK; Zali MR
J Cell Physiol; 2019 Apr; 234(4):4768-4777. PubMed ID: 30370522
[TBL] [Abstract][Full Text] [Related]
19. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
20. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
